Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EPRX
EUPRAXIA PHARMACEUTICALS INC.
NASDAQ
$7.50
▲ UP 0.67% (0.05)

KEY STATISTICS

Market Cap$251.10 M
52w High$9.32
52w Low$5.15
Dividend Yield—
Frequency—
P/E-7.14
Volume401.83K
Shares Out.33.48M

COMPANY

LEADERSHIP

James A. Helliwell
CHIEF EXECUTIVE
James A. Helliwell

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 5, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
49

PRICE TARGET

Target High$17.00
Target Low$17.00
Target Median$17.00
Target Consensus$17.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.—
NOV
3
TUE

PRICE

$7.50 ▲ UP 0.67% (+$0.05)
$7.40$7.50$7.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM7.50

About Eupraxia Pharmaceuticals Inc.

https://www.eupraxiapharma.com ↗

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biotech company developing innovative therapies, including EP-104IAR and EP-104GI, for pain relief, inflammatory conditions, and oncology.

INDUSTRY

Biotechnology

A PRODUCT EUPRAXIA PHARMACEUTICALS INC. IS KNOWN FOR

EP-104IAR
EP-104IAR

EP-104IAR is a Phase 3, FDA Fast Track-designated extended-release intra-articular corticosteroid for osteoarthritis knee pain, developed by Eupraxia to address an unmet medical need.

COMPETITORS

COMPETITOR
ANIK COMPARE
BVS COMPARE
HRTX COMPARE
PCRX COMPARE
TEVA COMPARE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
47.17%
HOLDERS
56
TOP 12 OF 56 · RANKED BY POSITION SIZE
Beutel, Goodman & Co Ltd.
3.7M sh · $27.93M
Affinity Asset Advisors, LLC
1.6M sh · $11.5M
Balyasny Asset Management L.P.
1.4M sh · $9.77M
Vivo Capital, LLC
1.4M sh · $9.77M
Scotia Capital Inc.
1.3M sh · $7.24M
Ikarian Capital, LLC
1.2M sh · $8.79M
Great Point Partners LLC
1.2M sh · $8.69M
Point72 Asset Management, L.P.
967.6K sh · $7.01M
Ally Bridge Group (Ny) LLC
915.0K sh · $5.4M
Ubs Group AG
762.6K sh · $5.52M
Redmile Group, LLC
700.0K sh · $5.07M
Rubric Capital Management LP
691.2K sh · $5M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OVERWEIGHT 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
SLS$13.78COMPARE
OBIO$4.78COMPARE
RNAC$8.88COMPARE
IVA$4.83COMPARE
TARA$3.95COMPARE
MDWD$13.17COMPARE
AARD$5.79COMPARE
NTHI$4.87COMPARE